- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the U.S. since October 2023.
- Why 4/10
- LOQTORZI is already FDA-approved and commercially launched for nasopharyngeal carcinoma, so there is no pending PDUFA or pivotal readout for this drug itself. The next hard catalyst is the expedited development path for the tagmokitug/toripalimab combination in esophageal cancer, but that is an investigational combination (tagmokitug is not yet approved), not a binary event for LOQTORZI alone. No single upcoming binary catalyst for LOQTORZI within the next 12 months.
LOQTORZI is a commercial-stage asset generating growing but still modest revenue (Q2 2026 net sales of $13.6M, up 15% sequentially). The company reported Q3 2026 results on November 9, 2026 with a $39.3M net loss and announced a strategic prioritization plan focusing on tagmokitug/toripalimab for esophageal cancer. Watch for Q3 LOQTORZI revenue trajectory and any updates on the expedited esophageal cancer development path. The stock trades near $0.84, down from a 52-week high of $2.62, reflecting the company's cash burn and pipeline-stage focus beyond LOQTORZI.
Price Chart
Executive Summary
LOQTORZI (toripalimab-tpzi) is an FDA-approved PD-1 inhibitor marketed by Coherus Oncology (NASDAQ: CHRS) for nasopharyngeal carcinoma (NPC). It was approved in October 2023 as the first China-developed PD-1 inhibitor to receive U.S. approval, and the only FDA-approved treatment specifically for NPC. Coherus licensed U.S. rights from Shanghai Junshi Biosciences. LOQTORZI is commercially launched with growing revenue (Q2 2026 net sales of $13.6M, up 15% sequentially), and management has guided for $57M-$62M in full-year 2026 LOQTORZI revenue and peak sales of $150M-$200M by mid-2028. The drug is also being studied in combination with Coherus' pipeline assets (tagmokitug, casdozokitug) in other cancers. On November 9, 2026, Coherus reported Q3 results with a $39.3M net loss and announced a strategic prioritization plan focusing on the tagmokitug/toripalimab combination in esophageal cancer.
How It Works
LOQTORZI is a PD-1 inhibitor, a type of immunotherapy. PD-1 is a protein on immune cells that acts as a brake, preventing them from attacking cancer cells. LOQTORZI blocks PD-1, releasing the brake and allowing the immune system to recognize and destroy cancer cells. It is described as a "next-generation" PD-1 inhibitor and was the first China-developed PD-1 inhibitor to receive FDA approval.
Trial Status
LOQTORZI (toripalimab-tpzi) was approved by the FDA in October 2023 for the first-line treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine, and as a single agent for recurrent/metastatic NPC after progression on platinum-based chemotherapy. The approval was based on the Phase 3 JUPITER-02 study and Phase 2 POLARIS-02 study. Six-year follow-up data from JUPITER-02 showed median overall survival of 64.8 months with LOQTORZI plus chemotherapy versus chemotherapy alone, nearly doubling survival. Coherus is also evaluating toripalimab in combination with its investigational CCR8 antibody tagmokitug in esophageal cancer and other solid tumors, with interim data reported in October 2026.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 LOQTORZI revenue and commercial update (reported November 9, 2026, after close).
- Expedited development path for tagmokitug/toripalimab combination in esophageal cancer, following promising interim data from October 28, 2026.
- Phase 1 data from ZM008 + LOQTORZI combination trial (collaboration with Zumutor Biologics).
- Full-year 2026 LOQTORZI revenue trajectory toward $57M-$62M guidance range.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Coherus Oncology, Inc. PRESS-RELEASE CHRS ·Originating report